Recent changes to the IMF, WTO and SPD: emerging global mode of regulation or social structure of accumulation for long wave upswing?

This paper examines the degree to which a new global mode of regulation (MOR) or social structure of accumulation (SSA) has emerged which may help to promote long wave upswing in the world economy. A series of institutional proxies are employed in this paper. Attention is given to the system-functions of global productivity and demand , through the performance of the prevailing system of production-distribution (SPD); global financial stability , proxied by the operations of the IMF; and global conflict resolution over trade issues, proxied through the workings of the WTO. The main findings are threefold. First, the SPD is only partially developed so as to promote productivity and demand. Second, some significant financial stability functions have been instigated through the IMF. And third, the WTO is undergoing major conflict due to the opposing policy proposals and criticisms by non-government organizations. This supports the conclusion that only limited success has been made in the emergence of a global MOR or SSA, not yet enough to promote (sustained) long wave upswing. The emergence of an effective global MOR or SSA to propel long wave upswing in the global economy is thus in the early-to-medium phase of development. Periodic uncertainty and deep recession (of an uneven character, interspersed with short-cycle upswings), are thus expected in the dominant economies during the early years of the twenty-first century until suitable institutional innovations emerge

Influence diagnostics for polyhazard models in the presence of covariates

Polyhazard model, Poly-Weibull distribution, Poly-log-logistic distribution, Influence diagnostics, Residual analysis,

Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

In this article, the name of the GLORIA-AF investigator Anastasios Kollias was given incorrectly as Athanasios Kollias in the Acknowledgements. The original article has been corrected.</jats:p

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

Abstract Background and purpose Prospectively collected data comparing the safety and effectiveness of individual non-vitamin K antagonists (NOACs) are lacking. Our objective was to directly compare the effectiveness and safety of NOACs in patients with newly diagnosed atrial fibrillation (AF). Methods In GLORIA-AF, a large, prospective, global registry program, consecutive patients with newly diagnosed AF were followed for 3 years. The comparative analyses for (1) dabigatran vs rivaroxaban or apixaban and (2) rivaroxaban vs apixaban were performed on propensity score (PS)-matched patient sets. Proportional hazards regression was used to estimate hazard ratios (HRs) for outcomes of interest. Results The GLORIA-AF Phase III registry enrolled 21,300 patients between January 2014 and December 2016. Of these, 3839 were prescribed dabigatran, 4015 rivaroxaban and 4505 apixaban, with median ages of 71.0, 71.0, and 73.0 years, respectively. In the PS-matched set, the adjusted HRs and 95% confidence intervals (CIs) for dabigatran vs rivaroxaban were, for stroke: 1.27 (0.79–2.03), major bleeding 0.59 (0.40–0.88), myocardial infarction 0.68 (0.40–1.16), and all-cause death 0.86 (0.67–1.10). For the comparison of dabigatran vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 1.16 (0.76–1.78), myocardial infarction 0.84 (0.48–1.46), major bleeding 0.98 (0.63–1.52) and all-cause death 1.01 (0.79–1.29). For the comparison of rivaroxaban vs apixaban, in the PS-matched set, the adjusted HRs were, for stroke 0.78 (0.52–1.19), myocardial infarction 0.96 (0.63–1.45), major bleeding 1.54 (1.14–2.08), and all-cause death 0.97 (0.80–1.19). Conclusions Patients treated with dabigatran had a 41% lower risk of major bleeding compared with rivaroxaban, but similar risks of stroke, MI, and death. Relative to apixaban, patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death. Rivaroxaban relative to apixaban had increased risk for major bleeding, but similar risks for stroke, MI, and death. Registration URL: https://www.clinicaltrials.gov. Unique identifiers: NCT01468701, NCT01671007. Date of registration: September 2013. Graphical abstract </jats:sec

Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

International audienceIn this article, the name of the GLORIA-AF investigator Anastasios Kollias was given incorrectly as Athanasios Kollias in the Acknowledgements. The original article has been corrected